| Wissenschaftl. Titel | A Phase 3, randomized study evaluating the efficacy and safety of TAR-210 Erdafitinib intravesical delivery system versus single agent intravesical chemotherapy in participants with Intermediate-risk Non-muscle Invasive Bladder Cancer(IR-NMIBC) and susceptible FGFR alterations |
| Erkrankung | |
| weitere Prüfzentren | |
| Kurzprotokoll | Kurzprotokoll |
erstellt 19.12.2024 Admin07
geändert 19.12.2024 Admin07